Biohaven Pharmaceutical Holding's (BHVN) CEO Vlad Coric on Q4 2021 Results - Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with significant revenue growth for NURTEC ODT, bolstered by a partnership with Pfizer for global expansion. Despite high R&D and SG&A expenses, the company's liquidity is robust. The Q&A session revealed optimism in product pipeline developments and regulatory approvals. However, some concerns were noted about profitability timelines. Considering the company's market cap and positive developments, a stock price increase of 2% to 8% is anticipated over the next two weeks.
BHVN Transcript
Biohaven Pharmaceutical Holding's (BHVN) CEO Vlad Coric on Q4 2021 Results - Earnings Call Transcript
Positive2-25
The earnings call highlights strong financial performance with significant revenue growth for NURTEC ODT, bolstered by a partnership with Pfizer for global expansion. Despite high R&D and SG&A expenses, the company's liquidity is robust. The Q&A session revealed optimism in product pipeline developments and regulatory approvals. However, some concerns were noted about profitability timelines. Considering the company's market cap and positive developments, a stock price increase of 2% to 8% is anticipated over the next two weeks.
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) CEO Vlad Coric on Q3 2021 Results - Earnings Call Transcript
Neutral11-9
Biohaven Pharmaceutical Holding Company's (BHVN) CEO Vlad Coric on Q2 2021 Results - Earnings Call Transcript
Neutral8-9
Biohaven Pharmaceutical Holding Company Ltd (BHVN) CEO Vladimir Coric on Q1 2021 Results - Earnings Call Transcript
Neutral5-10
BHVN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
